Guidance

Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies

Additional copies are available from:
Office of Training and Communications
Division of Communications Management
Drug Information Branch, HFD-210
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
(Internet) http://www.fda.gov/cder/guidance/index.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

December 2000
Procedural
TABLE OF CONTENTS

I. INTRODUCTION ....................................................................................................................................................... 1

II. BACKGROUND ........................................................................................................................................................... 1

III. DATA SOURCES ......................................................................................................................................................... 2
    A. RELIANCE ON DATA FROM CHERNOBYL ................................................................. 2
    B. THYROID CANCERS IN THE AFTERMATH OF CHERNOBYL ............................... 4

IV. CONCLUSIONS AND RECOMMENDATIONS ....................................................................................................... 5
    A. USE OF KI IN RADIATION EMERGENCIES: RATIONALE, EFFECTIVENESS, SAFETY ................................. 5
    B. KI USE IN RADIATION EMERGENCIES: TREATMENT RECOMMENDATIONS ................. 5

V. ADDITIONAL CONSIDERATIONS IN PROPHYLAXIS AGAINST THYROID RADIOIODINE EXPOSURE ............................................................................................................................. 7

VI. SUMMARY ............................................................................................................................................................... 8

BIBLIOGRAPHY .............................................................................................................................................................. 9
Iodide as a Thyroid Blocking Agent
in Radiation Emergencies

This draft guidance, when finalized, will represent the Food and Drug Administration’s current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

I. INTRODUCTION

This guidance updates the Food and Drug Administration (FDA) recommendation on using potassium iodide (KI) to reduce the risk of thyroid cancer in radiation emergencies involving the release of radioactive iodine. The recommendations provide guidance to state and local governments and assist the Environmental Protection Agency in providing guidance to other federal agencies on the development of emergency-response plans for prevention of adverse effects to the thyroid from internal irradiation in the event that radioiodines are accidentally released into the environment. These recommendations address KI dosage and the projected radiation exposure at which the drug should be used.

The revised recommendations were prepared by the Potassium Iodide Working Group, comprising scientists from the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) in collaboration with experts in the field from the National Institutes of Health (NIH). FDA’s revised recommendations are in general accordance with those of the World Health Organization (WHO), as expressed in its Guidelines for Iodine Prophylaxis Following Nuclear Accidents: Update 1999 (Baverstock 1999), although they differ in two respects (see section IV. B).

II. BACKGROUND

Under 44 CFR 351, the Federal Emergency Management Agency (FEMA) has established roles and responsibilities for Federal agencies in assisting State and local governments in their radiological emergency planning and preparedness activities. The Federal agencies, including the Department of Health and Human Services (HHS), are to carry out these roles and

1 This guidance has been prepared by the Potassium Iodide Working Group in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration.
responsibilities as members of the Federal Radiological Preparedness Coordinating Committee (FRPCC). Under 44 CFR 351.23(f), HHS is directed to provide guidance to State and local governments on the use of radioprotective substances and prophylactic use of drugs (e.g., potassium iodide (KI)) to reduce the radiation dose to specific organs. This guidance is to include information about dosage and projected radiation exposures at which such drugs should be used.

The FDA has provided guidance previously on the use of KI as a thyroid blocking agent. In the Federal Register of December 15, 1978, FDA announced its conclusion that KI is a safe and effective means by which to block uptake of radioiodines by the thyroid gland in a radiation emergency under certain specified conditions of use. In the Federal Register of June 29, 1982, FDA announced final recommendations on the administration of KI to the general public in a radiation emergency. Those recommendations were formulated after reviewing studies relating radiation dose to thyroid disease risk that rely on estimates of external thyroid irradiation after the nuclear detonations at Hiroshima and Nagasaki and analogous studies among children who had received therapeutic radiation to the head and neck. The final recommendations concluded that at a projected dose to the thyroid gland of 25 cGy\(^2\) or greater from ingested or inhaled radioiodines, the risks of short-term use of small quantities of KI were outweighed by the benefits of suppressing radioiodine-induced thyroid cancer. The amount of KI recommended at that time was 130 mg per day for adults and children above 1 year of age and 65 mg per day for children below 1 year of age. The guidance that follows revises our 1982 recommendations on the use of KI for thyroid cancer prophylaxis based on comprehensive review of the data relating radioiodine exposure to thyroid cancer risk accumulated in the aftermath of the 1986 Chernobyl reactor accident.

III. DATA SOURCES

A. Reliance on Data from Chernobyl

The recommendations contained in this guidance are derived from our review of data that have been reported in relation to the large number of thyroid cancers occurring as a result of the Chernobyl reactor accident of April 1986. These are the most comprehensive and reliable data available describing the relationship between thyroid radiation dose and risk for thyroid cancer. We have included in this guidance an extensive bibliography of the sources used in developing these revised recommendations.

In epidemiological studies investigating the relationship between thyroidal radioiodine exposure and risk of thyroid cancer, the estimation of thyroid radiation doses is a critical and complex aspect of the analyses. Estimates of exposure, both for individuals and across populations, have been reached in different studies by the variable combination of (1) direct thyroid measurements in a segment of the exposed population; (2) measurements of I-131 concentrations in the milk consumed by different groups (e.g., communities) and of the quantity of milk consumed; (3) inference from ground deposition of long-lived radioisotopes released coincidentally and

\(^2\) For the radiation produced by I-131, the radiation quality factor is approximately equal to 1, so that 1 cGy = 1 rem.
presumably in fixed ratios with radioiodines; and (4) reconstruction of the nature and extent of
the actual radiation release.

All estimates of individual and population exposure contain some degree of uncertainty. The
uncertainty is least for estimates of individual exposure based on direct thyroid measurements.
There is increasing uncertainty associated with estimates of community exposure that rely on
milk consumption estimates, and still greater uncertainty associated with community exposure
estimates derived by inference from ground deposition of long-lived radioisotopes. Exposure
estimates that rely heavily on release reconstructions are associated with the greatest uncertainty.
As explained below, the dosimetric data derived in the studies of individual and population
exposures following the Chernobyl accident, although not perfect, are unquestionably superior to
data from previous releases.

The Chernobyl reactor accident provides the best-documented example of a massive radiation
release in which large numbers of people across a broad geographical area were exposed acutely
to radioiodines released into the atmosphere. In contrast, the exposures resulting from radiation
releases from the Hanford Site in Washington State in the mid-1940s and in association with the
nuclear detonations at the Nevada Test Site in the 1950s were extended over years rather than
days to weeks, contributing to the difficulty in estimating radioactive dose in those potentially
exposed (Davis et al., 1999; Gilbert et al., 1998). The exposure of Marshall Islanders to fallout
from the nuclear detonation on Bikini in 1954 involved relatively few people, and although the
high rate of subsequent thyroid nodules and cancers in the exposed population was likely caused
in large part by radioiodines, the Marshall Islands data provide little insight into the dose-
response relationship between radioactive iodine exposure and thyroid cancer risk (Robbins and
Adams 1989).

Beginning within a week after the Chernobyl accident, direct measurements of thyroid exposure
were made in hundreds of thousands of individuals, across three republics of the former Soviet
Union (Robbins and Schneider 2000). Direct measurements of thyroid radioactivity are un-
available from the Hanford, Nevada Test Site, or Marshall Islands exposures. Indeed, the
estimates of thyroid radiation doses related to these releases rely heavily on release
reconstructions and, in the former two cases, on recall of the extent of milk consumption 40 to 50
years after the fact. In the Marshall Islands cohort, urinary radioiodine excretion data were
obtained and used in calculating exposure estimates. Milk consumption data were included as
components of some of the Chernobyl dosimetric analyses, but were complemented by critical
information from the direct thyroid measurements.

Because of the great uncertainty in the dose estimates from the Hanford and Nevada Test Site
exposures and due to the small numbers of thyroid cancers occurring in the populations
potentially exposed, the epidemiological studies of the excess thyroid cancer risk related to these
radioiodine releases are, at best, inconclusive. The results of these studies are inadequate to
refute overwhelming evidence from Chernobyl of a cause-effect relationship between thyroid
radioiodine deposition and thyroid cancer risk.

It is also notable that the thyroid radiation exposures after Chernobyl were virtually all internal,
from radioiodines. Despite some degree of uncertainty in the doses received, it is reasonable to
conclude that the contribution of external radiation was negligible for most individuals. This

distinguishes the Chernobyl exposures from those of the Marshall Islanders. Thus, the increase

in thyroid cancer seen after Chernobyl is directly attributable to ingested or inhaled radioiodines.

A comparable burden of excess thyroid cancers could conceivably accrue should U.S.

populations be similarly exposed in the event of a nuclear accident. This potential hazard

highlights the value of averting such risk by using KI as an adjunct to evacuation, sheltering, and

control of contaminated foodstuffs.

**B. Thyroid Cancers in the Aftermath of Chernobyl**

The Chernobyl reactor accident resulted in massive releases of I-131 and other radioiodines.

Beginning approximately 4 years after the accident, a sharp increase in the incidence of thyroid
cancer among children and adolescents in Belarus and Ukraine (areas covered by the radioactive
plume) was observed. In some regions, for the first 4 years of this striking increase, observed

cases of thyroid cancer among children aged 0-4 years at the time of the accident exceeded

expected cases by 30- to 60-fold. During the ensuing years, in the most heavily affected areas,

incidence is as much as 100-fold compared to pre-Chernobyl rates (Robbins and Schneider

2000). The majority of cases occurred in children who apparently received less than 30 cGy to

the thyroid (Astakhova et al., 1998). A few cases occurred in children exposed to estimated
doses of < 1 cGy; however, the uncertainty of these estimates and confounding by medical
radiation exposures leaves doubt as to the causal role of these doses of radioiodine (Souchkevitch

and Tsyb 1996).

We have concluded that the best dose-response information from Chernobyl shows a marked

increase in risk of thyroid cancer in children with exposures of 5 cGy or greater (Astakhova et

al., 1998; Ivanov et al., 1999; Kazakov et al., 1992). Among children born more than 6 months

after the accident in areas traversed by the radioactive plume, the incidence of thyroid cancer has

not exceeded preaccident rates, consistent with the short half-life of I-131.

The use of KI in Poland after the Chernobyl accident provides us with useful information

regarding its safety and tolerability in the general population. Approximately 10.5 million

children under age 16 and 7 million adults received at least one dose of KI. Of note, among

newborns receiving single doses of 15 mg KI, 0.37% (12/3214) showed transient increases in

TSH (thyroid stimulating hormone) and decreases in FT4 (free thyroxine). The side effects

among adults and children were generally mild and not clinically significant. Side effects

included gastrointestinal distress, which was reported more frequently in children (up to 2

percent) and rash (~1 percent in children and adults). Two allergic reactions were observed in

adults with known iodine sensitivity (Nauman and Wolff 1993).

Thus, the studies following the Chernobyl accident support the etiologic role of relatively small
doses of radioiodine in the dramatic increase in thyroid cancer among exposed children.

Furthermore, it appears that the increased risk occurs with a relatively short latency. Finally, the
Polish experience supports the use of KI as a safe and effective means by which to protect
against thyroid cancer caused by internal thyroid irradiation from inhalation of contaminated air
or ingestion of contaminated food and drink when exposure cannot be prevented by evacuation,
sheltering, or food and milk control.
IV. CONCLUSIONS AND RECOMMENDATIONS

A. Use of KI in radiation emergencies: rationale, effectiveness, safety

The direct relationship between exposure to inhaled or ingested radioiodines and thyroid cancer risk, if ever in doubt, is firmly established in the aftermath of the 1986 Chernobyl accident. For the reasons discussed above, the Chernobyl data provide the most reliable information available to date on the relationship between internal thyroid radioactive dose and cancer risk. They suggest that the risk of thyroid cancer is inversely related to age, and that, especially in young children, it may accrue at very low levels of radioiodine exposure. We have relied on the Chernobyl data to formulate our specific recommendations below.

The effectiveness of KI as a specific blocker of thyroid radioiodine uptake is well-established (Sternthal et al., 1980) as are the doses necessary for blockade. As such, it is reasonable to conclude that KI will likewise be effective in reducing the risk of thyroid cancer in individuals or populations at risk for inhalation or ingestion of radioiodines.

Short-term administration of KI at thyroid-blocking doses is safe and, in general, more so in children than adults. The risks of stable iodine administration include sialadenitis (of which no cases were reported in Poland among users after the Chernobyl accident), GI disturbances, and minor rashes. In addition, persons with known iodide sensitivity should avoid KI, as should individuals with dermatitis herpetiformis and hypocomplementemic vasculitis, extremely rare conditions associated with an increased risk of iodine hypersensitivity.

Thyroidal side effects of stable iodine include iodide-induced thyrotoxicosis, which is more common in older people and in iodide-deficient areas and usually requires repeated doses of stable iodine. In addition, iodide goiter and hypothyroidism, potential side effects more common in iodine-sufficient areas, require chronic high doses of stable iodine (Rubery 1990). In light of the preceding, individuals with multinodular goiter, Graves’ disease, and autoimmune thyroiditis should be treated with caution, especially if dosing extends beyond a few days. The vast majority of such individuals will be adults.

The transient hypothyroidism observed in 0.37 percent (12/3214) of neonates treated with KI in Poland after Chernobyl has been without sequelae to date. There is no question that the benefits of KI treatment to reduce the risk of thyroid cancer outweigh the risks of such treatment in neonates. Nevertheless, in light of the potential consequences of even transient hypothyroidism for intellectual development, we recommend that neonates (within the first month of life) treated with KI be monitored for this effect by measurement of TSH (and FT4, if indicated) and that thyroid hormone therapy be instituted in cases in which hypothyroidism develops (Fisher, Calaciura).

B. KI use in radiation emergencies: treatment recommendations
After careful review of the data from Chernobyl relating estimated thyroid radiation dose and cancer risk in exposed children, FDA recommends administration of KI to children aged 0-18 years and pregnant or lactating women in the event of a projected radiation dose to the thyroid of 5 cGy or greater. For adults up to 40 years of age, KI should be administered at a projected radiation dose of 10 cGy or greater. Adults over 40 need only take KI in the case of a projected large internal radiation dose to the thyroid (≥500 cGy) to prevent hypothyroidism (see table).

### Threshold Thyroid Radioactive Exposures and Recommended Doses of KI for Different Risk Groups

<table>
<thead>
<tr>
<th>Predicted Thyroid exposure (cGy)</th>
<th>KI dose (mg)</th>
<th># of 130 mg tablets</th>
<th># of 65 mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults over 40 yrs ≥500</td>
<td>130</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Adults over 18-40 yrs ≥10</td>
<td>130</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Pregnant or lactating women ≥5</td>
<td>65</td>
<td>1/2</td>
<td>1</td>
</tr>
<tr>
<td>Adolescents over 12-18 yrs*</td>
<td>65</td>
<td>1/2</td>
<td>1</td>
</tr>
<tr>
<td>Children over 3-12 yrs over 1 month-3 years</td>
<td>32</td>
<td>1/4</td>
<td>1/2</td>
</tr>
<tr>
<td>birth-1 month</td>
<td>16</td>
<td>1/8</td>
<td>1/4</td>
</tr>
</tbody>
</table>

* adolescents approaching adult size (≥70 kg) should receive the full adult dose (130 mg)

These FDA recommendations differ from those put forward in the World Health Organization (WHO) 1999 guidelines for iodine prophylaxis in two areas. WHO recommends the 130 mg dose of KI for adults and adolescents (over 12 years). For the sake of logistical simplicity in the dispensing and administration of KI to children, FDA recommends the 65 mg dose as standard for all school-age children while allowing for the adult dose (130 mg, 2 X 65 mg tablets) in adolescents approaching adult size. The other difference lies in the threshold for predicted exposure to those up to 18 years of age and to pregnant or lactating women that will trigger KI prophylaxis. WHO recommends a 1 cGy threshold for this group. As stated earlier, FDA has concluded from the Chernobyl data that the most reliable evidence supports a significant increase in the risk of childhood thyroid cancer at exposures of 5 cGy or greater.

The downward KI dose adjustment by age group, based on body size considerations, adheres to the principle of minimum effective dose. The recommended standard dose of KI for all school-age children is the same (65 mg). However, adolescents approaching adult size (i.e., ≥70 kg) should receive the full adult dose (130 mg) for maximal blockade of thyroid radiiodine uptake. Neonates ideally should receive the lowest dose (16 mg) of KI to minimize the risk of hypothyroidism during that critical phase of brain development (Calaciura et al., 1995). KI from tablets (either whole or fractions) or as fresh saturated KI solution may be diluted in milk or water and the appropriate volume administered to babies. As stated above, we recommend that neonates (within the first month of life) treated with KI be monitored for the potential...
development of hypothyroidism by measurement of TSH (and FT4, if indicated) and that thyroid
hormone therapy be instituted in cases in which hypothyroidism develops (Fisher 2000;
Calaciura et al., 1995).

Pregnant women should be given KI for their own protection and for that of the fetus, as iodine
(whether stable or radioactive) readily crosses the placenta. However, because of the risk of
blocking fetal thyroid function with excess stable iodine, repeat dosing with KI of pregnant
women should be avoided. Lactating females should be administered KI for their own
protection, as for other young adults, potentially to reduce the radioiodine content of the breast
milk, but not as a means to deliver KI to infants, who should get their KI directly. As for direct
administration of KI, stable iodine as a component of breast milk may also pose a risk of
hypothyroidism in nursing neonates. Therefore, if repeat dosing of the mother is necessary, the
nursing neonate should be monitored as recommended above.

The protective effect of KI lasts approximately 24 hours. For optimal prophylaxis, KI should
therefore be dosed daily, until a risk of significant exposure to radioiodines by either inhalation
or ingestion no longer exists. Individuals intolerant of KI at protective doses and pregnant and
lactating women (in whom repeat administration of KI raises particular safety issues, see above)
should be given priority with regard to other protective measures (i.e., sheltering, evacuation, and
control of the food supply).

V. ADDITIONAL CONSIDERATIONS IN PROPHYLAXIS AGAINST THYROID
RADIOIODINE EXPOSURE

Certain principles should guide emergency planning and implementation of KI prophylaxis in the
event of a radiation emergency. After the Chernobyl accident, across the affected populations,
thyroid radiation exposures occurred largely due to consumption of contaminated fresh cow's
milk (this contamination was the result of grazing on fields affected by radioactive fallout) and to
a much lesser extent by consumption of contaminated vegetables. In this or similar accidents,
for those residing in the immediate area of the accident or otherwise directly exposed to the
radioactive plume, inhalation of radioiodines may be a significant contributor to individual and
population exposures. As a practical matter, however, the risk of thyroid exposure from inhaled
radioiodines can only be assessed in retrospect, as it depends upon factors such as the magnitude
and rate of the radioiodine release, wind direction and other atmospheric conditions, and thus
may affect people both near to and far from the accident site.

For optimal protection against inhaled radioiodines, KI should be administered before or
immediately coincident with passage of the radioactive cloud, though KI may still have a
substantial protective effect even if taken 3 or 4 hours after exposure. Furthermore, if the release
of radioiodines into the atmosphere is protracted, then, of course, even delayed administration
may reap benefits by reducing, if incompletely, the total radiation dose to the thyroid.

Prevention of thyroid uptake of ingested radioiodines, once the plume has passed and radiation
protection measures (including KI) are in place, is best accomplished by food control measures
and not by repeated administration of KI. Because of radioactive decay, grain products and
canned milk or vegetables from sources affected by radioactive fallout, if stored for weeks to
months after production, pose no radiation risk. Thus, late KI prophylaxis at the time of
consumption is not required.

As time is of the essence in optimal prophylaxis with KI, timely administration to the public is a
critical consideration in planning the emergency response to a radiation accident.

VI. SUMMARY

FDA maintains that KI is a safe and effective means by which to prevent radioiodine uptake by
the thyroid gland, under certain specified conditions of use, and thereby obviate the risk of
thyroid cancer in the event of a radiation emergency. Based upon review of the literature, we
have proposed lower radioactive exposure thresholds for KI prophylaxis as well as lower doses
of KI for neonates, infants, and children than we recommended in 1982. As in our 1982 notice
in the Federal Register, FDA continues to recommend that radiation emergency response plans
include provisions, in the event of a radiation emergency, for informing the public about the
magnitude of the radiation hazard, about the manner of use of KI and its potential benefits and
risks, and for medical contact, reporting, and assistance systems. FDA also emphasizes that
emergency response plans and any systems for ensuring availability of KI to the public should
recognize the critical importance of KI administration in advance of exposure to radioiodine. As
in the past, FDA continues to work in an ongoing fashion with manufacturers of KI to ensure that
high-quality, safe, and effective KI products are available for purchase by consumers as well as
by state and local governments wishing to establish stores for emergency distribution.

KI provides protection only for the thyroid from radioiodines. It has no impact on the uptake by
the body of other radioactive materials and provides no protection against external irradiation of
any kind. FDA emphasizes that the use of KI should be as an adjunct to evacuation (itself not
always feasible), sheltering, and control of foodstuffs.

ACKNOWLEDGEMENTS

The KI Taskforce would like to extend special thanks to our members from the NIH: Drs. Jacob
Robbins and Jan Wolff of the National Institute of Diabetes, Digestive, and Kidney Diseases and
Dr. Andre Bouville of the National Cancer Institute. In addition, we would like to thank Dr.
David Becker of the New York Hospital, Cornell Medical Center for his valuable comments on
the draft.
BIBLIOGRAPHY


Robbins J, Schneider AB. “Thyroid Cancer following Exposure to Radioactive Iodine.” Reviews in Endocrine and Metabolic Disorders 2000; 1:197-203.


